TBRA Tobira Therapeutics Inc.

TOBIRA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

Rigrodsky & Long, P.A.:

  • Do you own shares of Tobira Pharmaceuticals, Inc. (NASDAQ CM: TBRA)?
  • Did you purchase any of your shares prior to September 20, 2016?
  • Do you think the proposed buyout price is too low?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Tobira Pharmaceuticals, Inc. (“Tobira” or the “Company”) (NASDAQ CM: TBRA) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Allergan plc (“Allergan”) (NYSE: AGN), in a transaction valued at approximately $1.695 billion.

Click here to learn more: http://rigrodskylong.com/investigations/tobira-pharmaceuticals-inc-tbra.

Under the terms of the agreement, shareholders of Tobira will receive an upfront payment of $28.35 per share, in cash, and up to $49.84 per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial milestones, for each share of Tobira common stock.

The investigation concerns whether Tobira’s board of directors failed to adequately shop the Company and obtain the best possible value for Tobira shareholders before entering into an agreement with Allergan.

If you own the common stock of Tobira and purchased your shares before September 20, 2016, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to [email protected], or at: http://rigrodskylong.com/investigations/tobira-pharmaceuticals-inc-tbra.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

EN
20/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tobira Therapeutics Inc.

 PRESS RELEASE

Tobira Therapeutics Announces Late-Breaking Oral Presentation of CENTA...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced the acceptance of the company’s late breaking abstract as an oral presentation at the American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (the Liver Meeting®), being held in Boston, MA from November 11-15, 2016. The abstract entitled “Cenicrivi...

 PRESS RELEASE

Tobira Therapeutics Announces Presentations Related to Cenicriviroc’...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced upcoming data presentations at the American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (the Liver Meeting®), being held in Boston, MA from November 11-15, 2016. Poster Presentation Details Presentation Date/Time: Saturday, November 12, ...

 PRESS RELEASE

TBRA SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into T...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Tobira Pharmaceuticals, Inc. (Nasdaq: TBRA) (“Tobira Pharmaceuticals” or the “Company”) relating to the proposed buyout of Tobira Pharmaceuticals by Allergan plc. Under the terms of the agreement, Tobira Pharmaceuticals shareholders are anticipated to receive an upfront payment of ...

 PRESS RELEASE

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into ...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Tobira Therapeutics, Inc. (“Tobira”) (NASDAQ:TBRA) stock prior to September 20, 2016. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Tobira to Allergan plc for $28.35 per share. The deal also includes up to $49.84 per share in Contingent Value Rights, payable upon the successful completion of certain milestone...

 PRESS RELEASE

TOBIRA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A....

WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Tobira Pharmaceuticals, Inc. (NASDAQ CM: TBRA)? Did you purchase any of your shares prior to September 20, 2016? Do you think the proposed buyout price is too low? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Tobira Pharmaceuticals, Inc. (“Tobira” or the “Company”) (...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch